Clinical Trials Browser

Interventional × Recurrent Squamous Cell Lung Carcinoma × Immunoglobulin G × Clear all

NCT03373760 2023-06-09

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Phase 2 Completed

67 enrolled 17 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02766335 2023-05-25

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Phase 2/3 Completed

116 enrolled 23 charts

Recurrent Squamous Cell Lung Carcinoma